Anti-Helicobacter pylori antibody status is associated with cancer mortality
A longitudinal analysis from the Japanese Daiko prospective cohort study
Bibliographic Data
| ID | 19593715 |
|---|---|
| Authors | Satoshi S Nishizuka (0000-0001-9178-790X, Iwate Medical University, corresponding author), Masahiro Nakatochi (0000-0002-1838-4837, Nagoya University, corresponding author), Yuka Koizumi (0000-0001-8440-0594, Iwate Medical University, corresponding author), Asahi Hishida (0000-0002-4867-0201, Nagoya University, corresponding author), Rieko Okada (0000-0002-6206-2501, Nagoya University, corresponding author), Sayo Kawai (0000-0002-5156-4880, Aichi Medical University, corresponding author), Yoichi Sutoh (0000-0002-1607-9759, Iwate Medical University, corresponding author), Keisuke Koeda (Iwate Medical University, corresponding author), Atsushi Shimizu (0000-0001-8307-2461, Iwate Medical University, corresponding author), Mariko Naito (0000-0003-3794-2643, Hiroshima University, corresponding author), Kenji Wakai (0000-0001-7388-7157, Nagoya University, corresponding author) |
| Editors | Ben Pascoe (0000-0001-6376-5121) |
| Year | 2023 |
| Volume | 3 |
| Issue | 2 |
| Pages | e0001125 |
| Publication date | 2023-02-08 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | PLOS Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Publisher | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0001125 |
| PMID | 36962964 |
| OpenAlex | W4319462057 |
| Language | EN |
| References cited | 55 |
Paradoxically, patients with advanced stomach cancer who are Helicobacter pylori -positive (HP + ) have a higher survival rate than those who are HP - . This finding suggests that HP infection has beneficial effects for cancer treatment. The present study examines whether HP + individuals have a lower likelihood of death from cancer than those who are HP - . Prospective cohort data ( n = 4,982 subjects enrolled in the DAIKO study between 2008–2010) were used to assess whether anti-HP antibody status was associated with cancer incidence. The median age in the primary registry was 53 years-old (range 35–69 years-old). Over the 8-year observation period there were 234 (4.7%) cancer cases in the cohort and 88 (1.8%) all-cause deaths. Urine anti-HP antibody data was available for all but one participant (n = 4,981; 99.98%). The number of HP + and HP - individuals was 1,825 (37%) and 3,156 (63%), respectively. Anti-HP antibody distribution per birth year revealed that earlier birth year was associated with higher HP + rates. With a birth year-matched cohort ( n = 3,376), all-cancer incidence was significantly higher in HP + individuals than those who were HP - (p = 0.00328), whereas there was no significant difference in the cancer death rate between HP + and HP - individuals (p = 0.888). Cox regression analysis for prognostic factors revealed that the hazards ratio of HP + was 1.59-fold (95%CI 1.17–2.26) higher than HP - in all-cancer incidence. Potential systemic effects of HP + status may contribute to reduced likelihood of death for patients after an initial diagnosis of cancer
Cancer · Cohort · Cohort study · Helicobacter pylori · Proportional hazards model · Prospective cohort study · Stomach cancer · Galectins and Cancer Biology · Gastric Cancer Management and Outcomes · Helicobacter pylori-related gastroenterology studies · Medicine · Gastroenterology · Internal Medicine
| Highly cited | No |
|---|